NEWS

Press Releases

04/21/2020
- Germline
- Neuro/Psych
Tempus Announces Prospective Psychiatric Study

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced its new prospective, pharmacogenomics study in psychiatry. The observational study aims to demonstrate the need for more transparent and reliable access to public data specific to a patient’s pharmacogenetic...
03/16/2020
- Clinical Trials
Tempus Announces the Addition of Dr. Kimberly Blackwell as Chief Medical Officer and Dr. Kenneth Carson as Vice President of Clinical Solutions

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announces the addition of Kimberly Blackwell, M.D., as Chief Medical Officer and Kenneth Carson, M.D., as Vice President of Clinical Solutions. “Our platform is designed to help clinicians make real-time,...
03/13/2020
- Cardiology
Tempus Announces $100 Million in Series G Financing

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced an additional $100 million financing at a post-money valuation of $5 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, and funds and accounts managed by T. Rowe Price. ...
02/03/2020
- Clinical Trials
- Genomic Sequencing
New Genomics Technology Puts Precision Oncology into Practice at Rush

Rush University Medical Center is the first health care organization to launch medical record company Epic’s module for genomic results, giving providers the tools they need to tailor patient care at the molecular level. Rush will use the module as part of its Precision Oncology Center to...
01/20/2020
- Cardiology
- Genomic Sequencing
Tempus Unveils AI-Enabled Smart Tests Across Disease Types

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, unveils its AI-enabled laboratory test (smart test) platform. Through its technology, laboratory tests are now able to be embedded with real-world evidence that deliver real-time, actionable insights to physicians, providing critical information...
01/15/2020
- Genomic Sequencing
Tempus Announces the Addition of Ari Caroline and Iker Huerga To Its Leadership Team

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announces the appointment of Ari Caroline and Iker Huerga as the Senior Vice President of Health Strategy and Vice President of Data Engineering and Strategy, respectively. Caroline and Huerga have joined Tempus...
12/12/2019
CVS Health Launches Transform Oncology Care™ Program to Help Improve Patient Outcomes and Lower Overall Costs

CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care...
12/11/2019
- Clinical Trials
- Genomic Sequencing
Tempus Announces the Acquisition of AKESOgen

CHICAGO and ATLANTA, December 11, 2019 — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced the acquisition of AKESOgen, an industry-leading commercial laboratory facility and provider of genomics and clinical trial precision medicine services based in Atlanta. AKESOgen is an integrated...
10/29/2019

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board Of Directors

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a...
09/30/2019
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a study in Nature Biotechnology, one of the industry’s leading peer-reviewed, scientific journals, surrounding its xT platform. The study, which focuses on 500 patient samples across diverse tumor types ana...

1 2 3 4 5 6 7 8 9 10 11 12 13 14

NEWS

Press Releases

Media Coverage

Additional Partnerships

Blog

Tempus Announces Prospective Psychiatric Study

Tempus Announces the Addition of Dr. Kimberly Blackwell as Chief Medical Officer and Dr. Kenneth Carson as Vice President of Clinical Solutions

Tempus Announces $100 Million in Series G Financing

New Genomics Technology Puts Precision Oncology into Practice at Rush

Tempus Unveils AI-Enabled Smart Tests Across Disease Types

Tempus Announces the Addition of Ari Caroline and Iker Huerga To Its Leadership Team

CVS Health Launches Transform Oncology Care™ Program to Help Improve Patient Outcomes and Lower Overall Costs

Tempus Announces the Acquisition of AKESOgen

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board Of Directors

Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities